TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02151448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
Study: NCT04339673

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: masseteric nerve block
Description: regional bloc of masseter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trigger point injection
Description: trigger point injection with local anesthetic

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: dry needling
Description: needling with acupuncture needles of trigger points in masseter
Study: NCT01714765

Intervention type: DRUG
Group type: OTHER
Intervention: Dovitinib
Description: Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg

Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
Study: NCT03570541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30 mL ropivacaine 0,375% administered on each side as bilateral TQL blocks
Study: NCT02151448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rintatolimod
Description: Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
Study: NCT01139528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bouquet pinning of the 5th metacarpal bone
Description: The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
Study: NCT02938143

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise (usual care)
Description: The control treatment is a painful heavy-load eccentric exercise program performed twice daily with 3 sets of 15 repetitions for 12 weeks on a 25° decline board. The downward component (eccentric component) will be performed with the symptomatic leg and the upward component (concentric phase) on the asymptomatic leg.
Study: NCT00065156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
Study: NCT03631589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Description: mesenchymal stem cells therapy
Study: NCT03624621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Remediation
Description: Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
Study: NCT02655731

Intervention type: DEVICE
Group type: OTHER
Intervention: PVI with HeartLight
Description: Catheter ablation
Study: NCT02353286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic insertion of biodegradable biliary stent
Description: Endoscopic insertion of biodegradable biliary stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic insertion of biodegradable biliary stent
Description: Endoscopic insertion of biodegradable biliary stent
Study: NCT03570541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Every six hours postoperative, all patients are administered 1 g of acetaminophen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Every six hours postoperative, all patients are administered 1 g of acetaminophen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Patient controlled analgesia
Description: PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenously administered morphine via PCA-pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: intravenously administered morphine via PCA-pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 30 ml saline 0,375% administered on each side as bilateral TQL blocks
Study: NCT03503604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hPV19 mAb
Description: Intravenous (IV) infusions, 4 and 6 milligrams per kilogram (mg/kg) every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hPV19 mAb
Description: Intravenous (IV) infusions, 4 and 6 milligrams per kilogram (mg/kg) every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hPV19 mAb
Description: Intravenous (IV) infusions, 6 milligrams per kilogram (mg/kg) every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hPV19 mAb
Description: Intravenous (IV) infusions, 6 milligrams per kilogram (mg/kg) every 3 weeks
Study: NCT03570541

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Description: On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of recovery-15 questionaire
Description: On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a short questionaire.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Quality of recovery-15 questionaire
Description: On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a short questionaire.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Orthostatic hypotension
Description: Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Orthostatic hypotension
Description: Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension.
Study: NCT00055692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given orally
Study: NCT03830346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument-assisted
Description: instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument-assisted
Description: instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).
Study: NCT01587040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408
Description: Pharmaceutical form: capsule or tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408
Description: Pharmaceutical form: capsule or tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form: capsule or tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form: capsule or tablet Route of administration: oral
Study: NCT02240641

Intervention type: DRUG
Intervention: Lacidipine

Intervention type: DRUG
Intervention: Diuretics

Intervention type: DRUG
Intervention: antihypertensive drugs
Study: NCT03606473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Description: is used to stimulate dopamine release in the brain

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]NPA
Description: PET radiotracer
Study: NCT02240641

Intervention type: DRUG
Intervention: alpha blockers

Intervention type: DRUG
Intervention: Angiotensin-Converting Enzyme Inhibitors

Intervention type: DRUG
Intervention: beta blockers
Study: NCT03301610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Education Delivery
Description: Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Verbal and Written Education
Description: Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
Study: NCT00970437

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Analysis System of Psychotherapy
Description: Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
Study: NCT03606473

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]NPA
Description: PET radiotracer
Study: NCT04353323

Intervention type: OTHER
Intervention: Blood sampling
Description: 3 blood samples (D0, D15 and D30) will be taken from each participant
Study: NCT00970437

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: System of Supportive Psychotherapy
Description: Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
Study: NCT01670721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFLIBERCEPT
Description: Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
Study: NCT03885024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retention Video
Description: Participants assigned to the retention training arm will watch a brief training video that will include information on how to retain peers in clinical trials.
Study: NCT01870505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Study: NCT03624621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT)
Description: 12 add-on sessions (20-minute long) after each group session to train cognitive domains.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: 12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Online games
Description: Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
Study: NCT05155228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Regulation and Competency
Description: Trauma informed psychotherapy intervention for children with a history of exposure to trauma and their caregivers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Supportive psychotherapy
Study: NCT01122667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet
Study: NCT04201561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium selenite pentahydrate
Description: High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
Study: NCT03548766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Homologous Blood Transfusion
Description: Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Blood Transfusion
Description: Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
Study: NCT02410720

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instruction leaflet
Description: Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction leaflet
Description: Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile App
Description: Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explanation of paper and application instructions
Description: The research fellow will explain instructions to patients
Study: NCT01870505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study: NCT03308500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity games
Description: The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
Study: NCT04540952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Capture Drape
Description: Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hysteroscopy Drape
Description: Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
Study: NCT01870505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study: NCT03812315

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Propolis chewing gum
Description: Children who will use chewing gum will be instructed to chew a gum for 20 minutes once after breakfast and another before bed time for two weeks.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Propolis mouthwash
Description: Children who will use mouthwash will be instructed to rinse with 10 ml for 60 seconds twice daily once after breakfast and another before bedtime for two weeks.
Study: NCT02410720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explanation of paper and application instructions
Description: The research fellow will explain instructions to patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Picoprep solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picoprep solution
Study: NCT01073865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD9393 (Zoladex) 10.8 mg
Description: 10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD9393 (Zoladex) 3.6 mg
Description: 3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
Study: NCT01504724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
Study: NCT04281381

Intervention type: DIAGNOSTIC_TEST
Intervention: Cross-sectional imaging
Description: MRI with gadolinium contrast will be the imaging modality of choice. In patients with contraindications to MRI who instead undergo baseline evaluation by CT scan, tumor evaluation will be by serial CT scans with IV contrast throughout the study period.
Study: NCT03925324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
Description: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.5 mL/kg Lactated Ringer's Solution
Study: NCT02995291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OraVerse
Description: 1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Water (Control)
Description: 1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
Study: NCT03799484

Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A will be administered to both sides

Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A will be administered to both sides

Intervention type: DRUG
Group type: OTHER
Intervention: 2.5% lidocaine/2.5% prilocaine
Description: 2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead

Intervention type: DEVICE
Group type: OTHER
Intervention: petrolatum ointment
Description: petrolatum ointment will be applied to one side of the forehead
Study: NCT01914484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor
Study: NCT03162601

Intervention type: PROCEDURE
Intervention: Neurovascular percutaneous intervention
Description: Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.